Literature DB >> 25464479

Neprilysin inhibitors preserve renal function in heart failure.

Fiona Bodey1, Ingrid Hopper2, Henry Krum2.   

Abstract

Entities:  

Keywords:  Heart failure; Neprilysin inhibitors; Renal dysfunction

Mesh：

Substances：

Year:  2014        PMID： 25464479     DOI： 10.1016/j.ijcard.2014.11.059

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  12 in total

1.  The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.

Authors:  Giuseppe Mulè; Alessandra Sorce; Emilio Nardi; Giulio Geraci; Santina Cottone
Journal:  Intern Emerg Med       Date:  2019-07-15       Impact factor: 3.397

Review 2.  Global cardiovascular protection in chronic kidney disease.

Authors:  Gema Ruiz-Hurtado; Pantelis Sarafidis; María S Fernández-Alfonso; Bernard Waeber; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

3.  Neurohormonal Blockade in Heart Failure.

Authors:  Thomas G von Lueder; Dipak Kotecha; Dan Atar; Ingrid Hopper
Journal:  Card Fail Rev       Date:  2017-04

4.  Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.

Authors:  Domenico Acanfora; Pietro Scicchitano; Chiara Acanfora; Roberto Maestri; Fernando Goglia; Raffaele Antonelli Incalzi; Alessandro Santo Bortone; Marco Matteo Ciccone; Massimo Uguccioni; Gerardo Casucci
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

Review 5.  New medical therapies for heart failure.

Authors:  Thomas G von Lueder; Henry Krum
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

Review 6.  Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.

Authors:  Juan Brignone; Kasper Bostlund Assersen; Mia Jensen; Boye L Jensen; Brian Kloster; Morten Jønler; Lars Lund
Journal:  Pflugers Arch       Date:  2021-04-12       Impact factor: 3.657

7.  Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Zhanna Kobalava; Yulia Kotovskaya; Oleg Averkov; Elena Pavlikova; Valentine Moiseev; Diego Albrecht; Priya Chandra; Surya Ayalasomayajula; Margaret F Prescott; Parasar Pal; Thomas H Langenickel; Pierre Jordaan; Iris Rajman
Journal:  Cardiovasc Ther       Date:  2016-08       Impact factor: 3.023

Review 8.  Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

Authors:  Bo Li; Yunhe Zhao; Bo Yin; Mengfei Helian; Xinmei Wang; Feng Chen; Hongxia Zhang; Hui Sun; Bin Meng; Fengshuang An
Journal:  Oncotarget       Date:  2017-05-31

Review 9.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

10.  A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.

Authors:  Daniel K Newhard; SeungWoo Jung; Randolph L Winter; Sue H Duran
Journal:  J Vet Intern Med       Date:  2018-08-07       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.